Entry |
|
Symbol |
PRKCB, PKC-beta, PKCB, PKCI(2), PKCbeta, PRKCB1, PRKCB2
|
Name |
(RefSeq) protein kinase C beta
|
KO |
|
Organism |
|
Pathway |
hsa01521 | EGFR tyrosine kinase inhibitor resistance |
hsa04070 | Phosphatidylinositol signaling system |
hsa04270 | Vascular smooth muscle contraction |
hsa04613 | Neutrophil extracellular trap formation |
hsa04650 | Natural killer cell mediated cytotoxicity |
hsa04662 | B cell receptor signaling pathway |
hsa04666 | Fc gamma R-mediated phagocytosis |
hsa04670 | Leukocyte transendothelial migration |
hsa04723 | Retrograde endocannabinoid signaling |
hsa04750 | Inflammatory mediator regulation of TRP channels |
hsa04919 | Thyroid hormone signaling pathway |
hsa04925 | Aldosterone synthesis and secretion |
hsa04928 | Parathyroid hormone synthesis, secretion and action |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications |
hsa04935 | Growth hormone synthesis, secretion and action |
hsa04960 | Aldosterone-regulated sodium reabsorption |
hsa04961 | Endocrine and other factor-regulated calcium reabsorption |
hsa04973 | Carbohydrate digestion and absorption |
hsa05022 | Pathways of neurodegeneration - multiple diseases |
hsa05163 | Human cytomegalovirus infection |
hsa05170 | Human immunodeficiency virus 1 infection |
hsa05207 | Chemical carcinogenesis - receptor activation |
|
Network |
|
Element |
N00023 | EGF-EGFR-PLCG-ERK signaling pathway |
N00024 | Mutation-activated EGFR to PLCG-ERK signaling pathway |
N00025 | EML4-ALK fusion kinase to PLCG-ERK signaling pathway |
N00227 | TGFA-EGFR-PLCG-PKC signaling pathway |
N00228 | TGFA-overexpression to PLCG-PKC signaling pathway |
N00413 | CXCR4-GNB/G-PLCB-PKC signaling pathway |
N00414 | HCMV US27 to CXCR4-GNB/G-PLCB-PKC signaling pathway |
N00428 | CCR5-GNB/G-PLCB/G-PKC signaling pathway |
N00546 | CXCL12-CXCR4-PKC-ERK signaling pathaway |
N00547 | HBV LHBs to PKC-ERK signaling pathway |
N00793 | TSH-DUOX2-TG signaling pathway |
N00869 | KISS1-KISS1R-PLCB-PKC signaling pathway |
N00873 | GnRH-GnRHR-PLCB-PKC signaling pathway |
N00882 | TAC3-TACR3-PLC-PKC signaling pathway |
N00918 | TRH-TRHR-PLCB-PKC signaling pathway |
N00953 | mGluR1-TRPC3 signaling pathway |
N01741 | Ca2+/TRPC3 signaling pathway |
|
Drug target |
Safingol hydrochloride: | D05785 |
|
Brite |
KEGG Orthology (KO) [BR:hsa00001]
09130 Environmental Information Processing
09132 Signal transduction
04010 MAPK signaling pathway
5579 (PRKCB)
04012 ErbB signaling pathway
5579 (PRKCB)
04014 Ras signaling pathway
5579 (PRKCB)
04015 Rap1 signaling pathway
5579 (PRKCB)
04310 Wnt signaling pathway
5579 (PRKCB)
04370 VEGF signaling pathway
5579 (PRKCB)
04064 NF-kappa B signaling pathway
5579 (PRKCB)
04066 HIF-1 signaling pathway
5579 (PRKCB)
04020 Calcium signaling pathway
5579 (PRKCB)
04070 Phosphatidylinositol signaling system
5579 (PRKCB)
04071 Sphingolipid signaling pathway
5579 (PRKCB)
04150 mTOR signaling pathway
5579 (PRKCB)
09140 Cellular Processes
09144 Cellular community - eukaryotes
04510 Focal adhesion
5579 (PRKCB)
04540 Gap junction
5579 (PRKCB)
09150 Organismal Systems
09151 Immune system
04613 Neutrophil extracellular trap formation
5579 (PRKCB)
04650 Natural killer cell mediated cytotoxicity
5579 (PRKCB)
04662 B cell receptor signaling pathway
5579 (PRKCB)
04666 Fc gamma R-mediated phagocytosis
5579 (PRKCB)
04670 Leukocyte transendothelial migration
5579 (PRKCB)
04062 Chemokine signaling pathway
5579 (PRKCB)
09152 Endocrine system
04911 Insulin secretion
5579 (PRKCB)
04929 GnRH secretion
5579 (PRKCB)
04912 GnRH signaling pathway
5579 (PRKCB)
04921 Oxytocin signaling pathway
5579 (PRKCB)
04935 Growth hormone synthesis, secretion and action
5579 (PRKCB)
04918 Thyroid hormone synthesis
5579 (PRKCB)
04919 Thyroid hormone signaling pathway
5579 (PRKCB)
04928 Parathyroid hormone synthesis, secretion and action
5579 (PRKCB)
04916 Melanogenesis
5579 (PRKCB)
04925 Aldosterone synthesis and secretion
5579 (PRKCB)
09153 Circulatory system
04270 Vascular smooth muscle contraction
5579 (PRKCB)
09154 Digestive system
04970 Salivary secretion
5579 (PRKCB)
04971 Gastric acid secretion
5579 (PRKCB)
04972 Pancreatic secretion
5579 (PRKCB)
04973 Carbohydrate digestion and absorption
5579 (PRKCB)
09155 Excretory system
04960 Aldosterone-regulated sodium reabsorption
5579 (PRKCB)
04961 Endocrine and other factor-regulated calcium reabsorption
5579 (PRKCB)
09156 Nervous system
04724 Glutamatergic synapse
5579 (PRKCB)
04727 GABAergic synapse
5579 (PRKCB)
04725 Cholinergic synapse
5579 (PRKCB)
04728 Dopaminergic synapse
5579 (PRKCB)
04726 Serotonergic synapse
5579 (PRKCB)
04720 Long-term potentiation
5579 (PRKCB)
04730 Long-term depression
5579 (PRKCB)
04723 Retrograde endocannabinoid signaling
5579 (PRKCB)
09157 Sensory system
04750 Inflammatory mediator regulation of TRP channels
5579 (PRKCB)
09159 Environmental adaptation
04713 Circadian entrainment
5579 (PRKCB)
09160 Human Diseases
09161 Cancer: overview
05200 Pathways in cancer
5579 (PRKCB)
05206 MicroRNAs in cancer
5579 (PRKCB)
05205 Proteoglycans in cancer
5579 (PRKCB)
05207 Chemical carcinogenesis - receptor activation
5579 (PRKCB)
05231 Choline metabolism in cancer
5579 (PRKCB)
09162 Cancer: specific types
05225 Hepatocellular carcinoma
5579 (PRKCB)
05214 Glioma
5579 (PRKCB)
05223 Non-small cell lung cancer
5579 (PRKCB)
09172 Infectious disease: viral
05170 Human immunodeficiency virus 1 infection
5579 (PRKCB)
05161 Hepatitis B
5579 (PRKCB)
05171 Coronavirus disease - COVID-19
5579 (PRKCB)
05164 Influenza A
5579 (PRKCB)
05163 Human cytomegalovirus infection
5579 (PRKCB)
09174 Infectious disease: parasitic
05146 Amoebiasis
5579 (PRKCB)
05140 Leishmaniasis
5579 (PRKCB)
05143 African trypanosomiasis
5579 (PRKCB)
09164 Neurodegenerative disease
05017 Spinocerebellar ataxia
5579 (PRKCB)
05022 Pathways of neurodegeneration - multiple diseases
5579 (PRKCB)
09165 Substance dependence
05031 Amphetamine addiction
5579 (PRKCB)
05032 Morphine addiction
5579 (PRKCB)
09166 Cardiovascular disease
05415 Diabetic cardiomyopathy
5579 (PRKCB)
09167 Endocrine and metabolic disease
04931 Insulin resistance
5579 (PRKCB)
04933 AGE-RAGE signaling pathway in diabetic complications
5579 (PRKCB)
09176 Drug resistance: antineoplastic
01521 EGFR tyrosine kinase inhibitor resistance
5579 (PRKCB)
09180 Brite Hierarchies
09181 Protein families: metabolism
01001 Protein kinases [BR:hsa01001]
5579 (PRKCB)
Enzymes [BR:hsa01000]
2. Transferases
2.7 Transferring phosphorus-containing groups
2.7.11 Protein-serine/threonine kinases
2.7.11.13 protein kinase C
5579 (PRKCB)
Protein kinases [BR:hsa01001]
Serine/threonine kinases: AGC group
PKC family [OT]
5579 (PRKCB)
|
SSDB |
|
Motif |
|
Other DBs |
|
Structure |
|
LinkDB |
|
Position |
16:23835983..24220611
|
AA seq |
671 aa
MADPAAGPPPSEGEESTVRFARKGALRQKNVHEVKNHKFTARFFKQPTFCSHCTDFIWGF
GKQGFQCQVCCFVVHKRCHEFVTFSCPGADKGPASDDPRSKHKFKIHTYSSPTFCDHCGS
LLYGLIHQGMKCDTCMMNVHKRCVMNVPSLCGTDHTERRGRIYIQAHIDRDVLIVLVRDA
KNLVPMDPNGLSDPYVKLKLIPDPKSESKQKTKTIKCSLNPEWNETFRFQLKESDKDRRL
SVEIWDWDLTSRNDFMGSLSFGISELQKASVDGWFKLLSQEEGEYFNVPVPPEGSEANEE
LRQKFERAKISQGTKVPEEKTTNTVSKFDNNGNRDRMKLTDFNFLMVLGKGSFGKVMLSE
RKGTDELYAVKILKKDVVIQDDDVECTMVEKRVLALPGKPPFLTQLHSCFQTMDRLYFVM
EYVNGGDLMYHIQQVGRFKEPHAVFYAAEIAIGLFFLQSKGIIYRDLKLDNVMLDSEGHI
KIADFGMCKENIWDGVTTKTFCGTPDYIAPEIIAYQPYGKSVDWWAFGVLLYEMLAGQAP
FEGEDEDELFQSIMEHNVAYPKSMSKEAVAICKGLMTKHPGKRLGCGPEGERDIKEHAFF
RYIDWEKLERKEIQPPYKPKARDKRDTSNFDKEFTRQPVELTPTDKLFIMNLDQNEFAGF
SYTNPEFVINV |
NT seq |
2016 nt +upstreamnt +downstreamnt
atggctgacccggctgcggggccgccgccgagcgagggcgaggagagcaccgtgcgcttc
gcccgcaaaggcgccctccggcagaagaacgtgcatgaggtcaagaaccacaaattcacc
gcccgcttcttcaagcagcccaccttctgcagccactgcaccgacttcatctggggcttc
gggaagcagggattccagtgccaagtttgctgctttgtggtgcacaagcggtgccatgaa
tttgtcacattctcctgccctggcgctgacaagggtccagcctccgatgacccccgcagc
aaacacaagtttaagatccacacgtactccagccccacgttttgtgaccactgtgggtca
ctgctgtatggactcatccaccaggggatgaaatgtgacacctgcatgatgaatgtgcac
aagcgctgcgtgatgaatgttcccagcctgtgtggcacggaccacacggagcgccgcggc
cgcatctacatccaggcccacatcgacagggacgtcctcattgtcctcgtaagagatgct
aaaaaccttgtacctatggaccccaatggcctgtcagatccctacgtaaaactgaaactg
attcccgatcccaaaagtgagagcaaacagaagaccaaaaccatcaaatgctccctcaac
cctgagtggaatgagacatttagatttcagctgaaagaatcggacaaagacagaagactg
tcagtagagatttgggattgggatttgaccagcaggaatgacttcatgggatctttgtcc
tttgggatttctgaacttcagaaagccagtgttgatggctggtttaagttactgagccag
gaggaaggcgagtacttcaatgtgcctgtgccaccagaaggaagtgaggccaatgaagaa
ctgcggcagaaatttgagagggccaagatcagtcagggaaccaaggtcccggaagaaaag
acgaccaacactgtctccaaatttgacaacaatggcaacagagaccggatgaaactgacc
gattttaacttcctaatggtgctggggaaaggcagctttggcaaggtcatgctttcagaa
cgaaaaggcacagatgagctctatgctgtgaagatcctgaagaaggacgttgtgatccaa
gatgatgacgtggagtgcactatggtggagaagcgggtgttggccctgcctgggaagccg
cccttcctgacccagctccactcctgcttccagaccatggaccgcctgtactttgtgatg
gagtacgtgaatgggggcgacctcatgtatcacatccagcaagtcggccggttcaaggag
ccccatgctgtattttacgctgcagaaattgccatcggtctgttcttcttacagagtaag
ggcatcatttaccgtgacctaaaacttgacaacgtgatgctcgattctgagggacacatc
aagattgccgattttggcatgtgtaaggaaaacatctgggatggggtgacaaccaagaca
ttctgtggcactccagactacatcgcccccgagataattgcttatcagccctatgggaag
tccgtggattggtgggcatttggagtcctgctgtatgaaatgttggctgggcaggcaccc
tttgaaggggaggatgaagatgaactcttccaatccatcatggaacacaacgtagcctat
cccaagtctatgtccaaggaagctgtggccatctgcaaagggctgatgaccaaacaccca
ggcaaacgtctgggttgtggacctgaaggcgaacgtgatatcaaagagcatgcatttttc
cggtatattgattgggagaaacttgaacgcaaagagatccagcccccttataagccaaaa
gctagagacaagagagacacctccaacttcgacaaagagttcaccagacagcctgtggaa
ctgacccccactgataaactcttcatcatgaacttggaccaaaatgaatttgctggcttc
tcttatactaacccagagtttgtcattaatgtgtag |